845 related articles for article (PubMed ID: 16600306)
41. Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis.
Koga M; Yuki N; Hirata K
J Neuroimmunol; 1999 May; 96(2):245-50. PubMed ID: 10337924
[TBL] [Abstract][Full Text] [Related]
42. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
Yuki N
Lancet Infect Dis; 2001 Aug; 1(1):29-37. PubMed ID: 11871407
[TBL] [Abstract][Full Text] [Related]
43. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
Komagamine T; Yuki N
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):391-400. PubMed ID: 16918391
[TBL] [Abstract][Full Text] [Related]
44. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a.
Tatsumoto M; Koga M; Gilbert M; Odaka M; Hirata K; Kuwabara S; Yuki N
J Neuroimmunol; 2006 Aug; 177(1-2):201-8. PubMed ID: 16844234
[TBL] [Abstract][Full Text] [Related]
45. The immunobiology of Guillain-Barré syndromes.
Willison HJ
J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123
[TBL] [Abstract][Full Text] [Related]
46. [Pathogenesis of axonal Guillain-Barré syndrome].
Yuki N
Rinsho Shinkeigaku; 2007 Jan; 47(1):1-7. PubMed ID: 17491330
[TBL] [Abstract][Full Text] [Related]
47. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation.
Kuijf ML; Samsom JN; van Rijs W; Bax M; Huizinga R; Heikema AP; van Doorn PA; van Belkum A; van Kooyk Y; Burgers PC; Luider TM; Endtz HP; Nieuwenhuis EE; Jacobs BC
J Immunol; 2010 Jul; 185(1):748-55. PubMed ID: 20525894
[TBL] [Abstract][Full Text] [Related]
48. [A case of Guillain-Barré syndrome after Campylobacter jejuni enterocolitis: anti-ganglioside antibody levels with or without Guillain-Barré syndrome].
Watanabe H; Shindo K; Nakamura Y; Nagamatsu M; Shiozawa Z; Kusunoki S
Rinsho Shinkeigaku; 2001 Sep; 41(9):625-7. PubMed ID: 11968750
[TBL] [Abstract][Full Text] [Related]
49. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
[TBL] [Abstract][Full Text] [Related]
50. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome.
Yuki N
J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700
[TBL] [Abstract][Full Text] [Related]
51. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.
Nagashima T; Koga M; Odaka M; Hirata K; Yuki N
Arch Neurol; 2007 Oct; 64(10):1519-23. PubMed ID: 17923636
[TBL] [Abstract][Full Text] [Related]
52. The sialic acid residue is a crucial component of C. jejuni lipooligosaccharide ganglioside mimicry in the induction Guillain-Barré syndrome.
Xiang SL; Zhong M; Cai FC; Deng B; Zhang XP
J Neuroimmunol; 2006 May; 174(1-2):126-32. PubMed ID: 16567003
[TBL] [Abstract][Full Text] [Related]
53. Anti-ganglioside complex antibodies associated with severe disability in GBS.
Kaida K; Morita D; Kanzaki M; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S
J Neuroimmunol; 2007 Jan; 182(1-2):212-8. PubMed ID: 17113161
[TBL] [Abstract][Full Text] [Related]
54. Human gangliosides and bacterial lipo-oligosaccharides in the development of autoimmune neuropathies.
Yuki N
Methods Mol Biol; 2010; 600():51-65. PubMed ID: 19882120
[TBL] [Abstract][Full Text] [Related]
55. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes.
Godschalk PC; Kuijf ML; Li J; St Michael F; Ang CW; Jacobs BC; Karwaski MF; Brochu D; Moterassed A; Endtz HP; van Belkum A; Gilbert M
Infect Immun; 2007 Mar; 75(3):1245-54. PubMed ID: 17261613
[TBL] [Abstract][Full Text] [Related]
56. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections.
Hao Q; Saida T; Kuroki S; Nishimura M; Nukina M; Obayashi H; Saida K
J Neuroimmunol; 1998 Jan; 81(1-2):116-26. PubMed ID: 9521613
[TBL] [Abstract][Full Text] [Related]
57. Association of Anti-GT1a Antibodies with an Outbreak of Guillain-Barré Syndrome and Analysis of Ganglioside Mimicry in an Associated Campylobacter jejuni Strain.
Zhang M; Gilbert M; Yuki N; Cao F; Li J; Liu H; Li Q; Meng F; Zhang J
PLoS One; 2015; 10(7):e0131730. PubMed ID: 26197476
[TBL] [Abstract][Full Text] [Related]
58. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh.
Islam Z; Jacobs BC; van Belkum A; Mohammad QD; Islam MB; Herbrink P; Diorditsa S; Luby SP; Talukder KA; Endtz HP
Neurology; 2010 Feb; 74(7):581-7. PubMed ID: 20157160
[TBL] [Abstract][Full Text] [Related]
59. Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiology.
Yuki N; Kuwabara S
J Peripher Nerv Syst; 2007 Dec; 12(4):238-49. PubMed ID: 18042134
[TBL] [Abstract][Full Text] [Related]
60. Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients.
Strid MA; Engberg J; Larsen LB; Begtrup K; Mølbak K; Krogfelt KA
Clin Diagn Lab Immunol; 2001 Mar; 8(2):314-9. PubMed ID: 11238214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
